ARUP Laboratories to Develop and Commercialize Clinical Laboratory Assays Based on Luminex's LabMAP Technology

- ARUP Laboratories Currently Offers Two Multi-Analyte Applications Based On

Luminex's LabMAP System Which Include a Profile of Pneumococcal Antibody

Assays and a Profile of Mononuclear Cell Cytokine Assays -



Apr 17, 2001, 01:00 ET from Luminex Corporation and ARUP Laboratories

    SALT LAKE CITY and AUSTIN, Texas, April 17 /PRNewswire/ -- ARUP
 Laboratories, a national, specialty diagnostic reference laboratory, and
 Luminex Corporation (Nasdaq:   LMNX) announced today that they have entered into
 a strategic partnership permitting ARUP to develop and commercialize a wide
 range of clinical laboratory assays based on Luminex's proprietary Multi-
 Analyte Profiling (LabMAP(TM)) technology.  The strategic partnership gives
 ARUP broad access to Luminex's proprietary LabMAP system to perform both
 immunological applications, such as the pneumococcal antibody profile, as well
 as various molecular diagnostic tests.  Luminex will receive royalty payments
 based on the sale of diagnostic tests developed by ARUP.
     ARUP is now offering two new assays utilizing the Luminex LabMAP
 technology.  The first application is a multiplexed assay that detects
 antibody levels to pneumococcal polysaccharides in patients receiving
 pneumococcal vaccine, and is useful for assessing patients with recurrent or
 persisting bacterial infections due to Streptococcus pneumoniae.  The second
 application is a panel that simultaneously measures mononuclear cell cytokine
 responses to mitogens and specific antigens, and is useful in the evaluation
 of patients with recurrent infections, allergic disorders, immune deficiency
 and parasitic infections.  ARUP is the first national, esoteric reference
 laboratory to offer multi-analyte testing for these purposes using Luminex's
 proprietary LabMAP technology.
     Harry R. Hill, M.D., Executive Director of the ARUP Institute for Clinical
 and Experimental Pathology, and Professor and Head of Clinical Pathology at
 the University of Utah, stated "we feel the new multi-analyte Luminex
 technology represents an important new wave of laboratory testing which
 permits the simultaneous analysis of a number of different analytes in a
 single reaction."
     ARUP's pneumococcal antibody assay, for example, detects the antibody
 levels of every pneumococcal polysaccharide type present in the new Prevnar 7
 conjugated vaccine (Wyeth Lederle Vaccines), which is for infants less than
 two years of age, and also detects the antibody levels of 14 pneumococcal
 polysaccharide types in the Pneumovax 23 and Pnu-Immune 23 vaccines.  In turn,
 ARUP's multiplex panel for the measurement of mononuclear cell cytokine
 responses to mitogens (phytohemagglutinin, concanavalin A, and pokeweed
 mitogen) and specific antigens (tetanus and candida) simultaneously detects
 the TH1-type cytokines referred to as interferon gamma, IL2, and IL12, as well
 as the TH2-type cytokines referred to as IL4, 6, and 10.
     "We are delighted that ARUP Laboratories, a national leader in the
 clinical reference laboratory industry, has adopted our LabMAP system," said
 John Porter, Director of Business Development for Luminex.  "Clinical
 reference labs continue to search for new technologies that have the ability
 to expand existing testing menus while reducing internal costs and our
 strategic partnership with ARUP is another powerful validation of how our
 system can be an integral solution in the clinical industry."
     The Luminex LabMAP technology is based on microscopic beads called
 microspheres that are internally labeled with two different fluorophores.
 Different antigens, antibodies, or nucleotide probes can then be attached to
 these uniquely labeled beads and a third fluorophore (bound to a secondary
 antibody or nucleotide probe) can be used to detect and to quantitate the
 antibodies, microbial antigens, or RNA or DNA in a patient's sample.  This
 technology allows up to a maximum of 100 different substances to be
 quantitated within a single assay, improving disease diagnoses as well as
 decreasing cost and turnaround times.
 
     About ARUP Laboratories
     ARUP Laboratories is national full-service reference laboratory owned by
 the Department of Pathology at the University of Utah Health Sciences Center.
 ARUP is a worldwide leader in innovative laboratory research and development,
 led by the efforts of the ARUP Institute for Clinical and Experimental
 Pathology, LLC.  With revenue of greater than $100 million and more than
 1200 employees, ARUP offers over 2,000 tests and test combinations ranging
 from routine cytology screens to highly esoteric molecular and genetic assays.
 ARUP's clients include university teaching hospitals, multihospital groups,
 major commercial laboratories, group purchasing organizations, military and
 government facilities, major clinics, and major pharmaceutical firms.  Further
 information on ARUP Laboratories can be obtained on the Internet at
 http://www.aruplab.com.
 
     About Luminex Corporation
     Luminex Corporation develops, manufactures and markets proprietary
 biological testing technologies with applications throughout the life sciences
 industry.  The company's LabMAP system is an open-architecture, multi-analyte
 technology platform that delivers fast, accurate and cost-effective bioassay
 results to markets as diverse as pharmaceutical drug discovery, clinical
 diagnostics and biomedical research, including the genomics and proteomics
 research markets.  The company's LabMAP technology is sold worldwide and is
 already in use in leading research laboratories as well as major
 pharmaceutical, diagnostic and biotechnology companies.  Further information
 on Luminex Corporation or LabMAP can be obtained on the Internet at
 http://www.luminexcorp.com.
 
     Statements made in this press release that express Luminex's or
 management's intentions, plans, beliefs, expectations or predictions of future
 events are forward-looking statements.  The words "believe," "expect,"
 "intend," "estimate," "anticipate," "will" and similar expressions are
 intended to further identify such forward-looking statements.  It is important
 to note that the company's actual results or performance could differ
 materially from those anticipated or projected in such forward-looking
 statements.  Factors that could cause Luminex's actual results or performance
 to differ materially include risks and uncertainties relating to market demand
 and acceptance of Luminex's products, the company's dependence on strategic
 partners for development and distribution of products, competition, Luminex's
 ability to scale-up manufacturing operations, potential shortages of
 components and the timing of regulatory approvals, as well as the risks
 discussed under the heading "Factors That May Affect Future Results" in
 Luminex's annual report on Form 10-K for the year ended December 31, 2000, as
 filed with the Securities and Exchange Commission.  The forward-looking
 statements contained herein represent the judgment of Luminex as of the date
 of this press release, and Luminex expressly disclaims any intent, obligation
 or undertaking to update or revise such forward-looking statements to reflect
 any change in Luminex's expectations with regard thereto or any change in
 events, conditions or circumstances on which any such statements are based.
 
     Editor's Note:
     Information about ARUP Laboratories may be found on the Internet at
 http://www.arup-lab.com.
 
     Information on Luminex and LabMAP may be found on the Internet at
 http://www.luminexcorp.com.
 
      ARUP Laboratories                  Luminex Corporation
      (801) 583-2787 ext. 2184           (512) 219-8020
      Harry R. Hill, M.D.                John M. Porter
      Executive Manager,                 Director of Business Development
      ARUP Institute for Clinical and
       Experimental Pathology
 
      (801) 584-5188
      Ronald L. Weiss, M.D., M.B.A.
      Director of Laboratories
 
 

SOURCE Luminex Corporation and ARUP Laboratories
    SALT LAKE CITY and AUSTIN, Texas, April 17 /PRNewswire/ -- ARUP
 Laboratories, a national, specialty diagnostic reference laboratory, and
 Luminex Corporation (Nasdaq:   LMNX) announced today that they have entered into
 a strategic partnership permitting ARUP to develop and commercialize a wide
 range of clinical laboratory assays based on Luminex's proprietary Multi-
 Analyte Profiling (LabMAP(TM)) technology.  The strategic partnership gives
 ARUP broad access to Luminex's proprietary LabMAP system to perform both
 immunological applications, such as the pneumococcal antibody profile, as well
 as various molecular diagnostic tests.  Luminex will receive royalty payments
 based on the sale of diagnostic tests developed by ARUP.
     ARUP is now offering two new assays utilizing the Luminex LabMAP
 technology.  The first application is a multiplexed assay that detects
 antibody levels to pneumococcal polysaccharides in patients receiving
 pneumococcal vaccine, and is useful for assessing patients with recurrent or
 persisting bacterial infections due to Streptococcus pneumoniae.  The second
 application is a panel that simultaneously measures mononuclear cell cytokine
 responses to mitogens and specific antigens, and is useful in the evaluation
 of patients with recurrent infections, allergic disorders, immune deficiency
 and parasitic infections.  ARUP is the first national, esoteric reference
 laboratory to offer multi-analyte testing for these purposes using Luminex's
 proprietary LabMAP technology.
     Harry R. Hill, M.D., Executive Director of the ARUP Institute for Clinical
 and Experimental Pathology, and Professor and Head of Clinical Pathology at
 the University of Utah, stated "we feel the new multi-analyte Luminex
 technology represents an important new wave of laboratory testing which
 permits the simultaneous analysis of a number of different analytes in a
 single reaction."
     ARUP's pneumococcal antibody assay, for example, detects the antibody
 levels of every pneumococcal polysaccharide type present in the new Prevnar 7
 conjugated vaccine (Wyeth Lederle Vaccines), which is for infants less than
 two years of age, and also detects the antibody levels of 14 pneumococcal
 polysaccharide types in the Pneumovax 23 and Pnu-Immune 23 vaccines.  In turn,
 ARUP's multiplex panel for the measurement of mononuclear cell cytokine
 responses to mitogens (phytohemagglutinin, concanavalin A, and pokeweed
 mitogen) and specific antigens (tetanus and candida) simultaneously detects
 the TH1-type cytokines referred to as interferon gamma, IL2, and IL12, as well
 as the TH2-type cytokines referred to as IL4, 6, and 10.
     "We are delighted that ARUP Laboratories, a national leader in the
 clinical reference laboratory industry, has adopted our LabMAP system," said
 John Porter, Director of Business Development for Luminex.  "Clinical
 reference labs continue to search for new technologies that have the ability
 to expand existing testing menus while reducing internal costs and our
 strategic partnership with ARUP is another powerful validation of how our
 system can be an integral solution in the clinical industry."
     The Luminex LabMAP technology is based on microscopic beads called
 microspheres that are internally labeled with two different fluorophores.
 Different antigens, antibodies, or nucleotide probes can then be attached to
 these uniquely labeled beads and a third fluorophore (bound to a secondary
 antibody or nucleotide probe) can be used to detect and to quantitate the
 antibodies, microbial antigens, or RNA or DNA in a patient's sample.  This
 technology allows up to a maximum of 100 different substances to be
 quantitated within a single assay, improving disease diagnoses as well as
 decreasing cost and turnaround times.
 
     About ARUP Laboratories
     ARUP Laboratories is national full-service reference laboratory owned by
 the Department of Pathology at the University of Utah Health Sciences Center.
 ARUP is a worldwide leader in innovative laboratory research and development,
 led by the efforts of the ARUP Institute for Clinical and Experimental
 Pathology, LLC.  With revenue of greater than $100 million and more than
 1200 employees, ARUP offers over 2,000 tests and test combinations ranging
 from routine cytology screens to highly esoteric molecular and genetic assays.
 ARUP's clients include university teaching hospitals, multihospital groups,
 major commercial laboratories, group purchasing organizations, military and
 government facilities, major clinics, and major pharmaceutical firms.  Further
 information on ARUP Laboratories can be obtained on the Internet at
 http://www.aruplab.com.
 
     About Luminex Corporation
     Luminex Corporation develops, manufactures and markets proprietary
 biological testing technologies with applications throughout the life sciences
 industry.  The company's LabMAP system is an open-architecture, multi-analyte
 technology platform that delivers fast, accurate and cost-effective bioassay
 results to markets as diverse as pharmaceutical drug discovery, clinical
 diagnostics and biomedical research, including the genomics and proteomics
 research markets.  The company's LabMAP technology is sold worldwide and is
 already in use in leading research laboratories as well as major
 pharmaceutical, diagnostic and biotechnology companies.  Further information
 on Luminex Corporation or LabMAP can be obtained on the Internet at
 http://www.luminexcorp.com.
 
     Statements made in this press release that express Luminex's or
 management's intentions, plans, beliefs, expectations or predictions of future
 events are forward-looking statements.  The words "believe," "expect,"
 "intend," "estimate," "anticipate," "will" and similar expressions are
 intended to further identify such forward-looking statements.  It is important
 to note that the company's actual results or performance could differ
 materially from those anticipated or projected in such forward-looking
 statements.  Factors that could cause Luminex's actual results or performance
 to differ materially include risks and uncertainties relating to market demand
 and acceptance of Luminex's products, the company's dependence on strategic
 partners for development and distribution of products, competition, Luminex's
 ability to scale-up manufacturing operations, potential shortages of
 components and the timing of regulatory approvals, as well as the risks
 discussed under the heading "Factors That May Affect Future Results" in
 Luminex's annual report on Form 10-K for the year ended December 31, 2000, as
 filed with the Securities and Exchange Commission.  The forward-looking
 statements contained herein represent the judgment of Luminex as of the date
 of this press release, and Luminex expressly disclaims any intent, obligation
 or undertaking to update or revise such forward-looking statements to reflect
 any change in Luminex's expectations with regard thereto or any change in
 events, conditions or circumstances on which any such statements are based.
 
     Editor's Note:
     Information about ARUP Laboratories may be found on the Internet at
 http://www.arup-lab.com.
 
     Information on Luminex and LabMAP may be found on the Internet at
 http://www.luminexcorp.com.
 
      ARUP Laboratories                  Luminex Corporation
      (801) 583-2787 ext. 2184           (512) 219-8020
      Harry R. Hill, M.D.                John M. Porter
      Executive Manager,                 Director of Business Development
      ARUP Institute for Clinical and
       Experimental Pathology
 
      (801) 584-5188
      Ronald L. Weiss, M.D., M.B.A.
      Director of Laboratories
 
 SOURCE  Luminex Corporation and ARUP Laboratories